Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23876414 | 0.85 | GAA (0.39) | ALOX5GAANPSR1MAPTMEN1 | |
| SCHEMBL23876383 | 0.82 | ALOX5 (0.52) | ALOX5GAANPSR1MAPTSMN1; SMN2 | |
| SCHEMBL13066853 | 0.77 | MAOA (0.39) | ALOX5AHRMAOAMAOB | |
| Phenoxazine SCHEMBL7862 | 0.72 | ALOX5 (1.00) | ALOX5GAANPSR1MAPTMEN1 | |
| Phenoxazine SCHEMBL6310178 | 0.72 | ALOX5 (1.00) | ALOX5GAANPSR1MAPTMEN1 | |
| Phenoxazine SCHEMBL29355714 | 0.72 | ALOX5 (1.00) | ALOX5GAANPSR1MAPTMEN1 | |
| Phenoxazine SCHEMBL28844098 | 0.72 | ALOX5 (1.00) | ALOX5GAANPSR1MAPTMEN1 | |
| SCHEMBL23876674 | 0.72 | ALOX5 (0.41) | ALOX5GAANPSR1MAPTMEN1 | |
| SCHEMBL23876702 | 0.71 | NOX1 (0.54) | GAANPSR1MAPTMEN1LMNA | |
| Phenoxazine SCHEMBL5808288 | 0.70 | ALOX5 (0.94) | ALOX5GAANPSR1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230337537-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20230337537-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| WO-2021191058-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230337537-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | L1CAM, PIEZO1, GPX1 | ALOX5 2239/4885GAA 2508/4885NPSR1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.